Core Insights - Nuwellis, Inc. has appointed Carisa Schultz as Chief Financial Officer, effective February 2, 2026, to enhance its financial leadership in the medical technology sector focused on precision cardiorenal care [1][4]. Company Overview - Nuwellis, Inc. is a medical technology company that develops precision fluid management technologies aimed at improving patient care across the cardiorenal continuum, addressing both acute and chronic conditions [4]. - The company's product portfolio includes both commercially available and development-stage technologies that focus on safety, precision, and scalability for various patient populations [4]. Leadership Experience - Carisa Schultz has extensive experience in healthcare finance, having served as Vice President of Finance at NeueHealth, where she led enterprise finance, treasury, and corporate development [2]. - Schultz's background includes roles at Boston Scientific and various leadership positions in public and private healthcare organizations, along with experience in Big Four public accounting [3]. Product Highlight - The Aquadex SmartFlow® System is designed to remove excess fluid from patients suffering from hypervolemia, with indications for both temporary and extended use in adult and pediatric patients [5].

Core Viewpoint - Nuwellis, Inc. has entered into a Securities Purchase Agreement to acquire Rendiatech Ltd., enhancing its capabilities in real-time kidney function monitoring and expanding its cardiorenal platform [1][2]. Group 1: Transaction Details - The acquisition of Rendiatech is expected to close upon meeting customary closing conditions, positioning Nuwellis to broaden its portfolio into real-time renal diagnostics [1][5]. - The transaction has been approved by the boards of directors of both Nuwellis and Rendiatech [5]. Group 2: Strategic Implications - This acquisition represents a strategic move for Nuwellis, allowing the company to extend its capabilities beyond therapeutic fluid management into real-time renal monitoring, which aligns with its long-term vision [2][4]. - Nuwellis plans to leverage its existing commercial infrastructure and clinical relationships to integrate Rendiatech's technology effectively [4]. Group 3: Technology Overview - Rendiatech's Clarity™ system offers automated, continuous renal monitoring through precise urine-output measurement, aiming to replace manual collection methods [3][9]. - The addition of the Clarity system is expected to lay the groundwork for future advancements in urine-based analytics and comprehensive kidney function assessment [3].